AEHR TEST SYSTEMS (AEHR) — Fundamental Analysis

Aehr Test Systems is a small-cap semiconductor equipment maker that rode a wave of silicon carbide (SiC) wafer-level burn-in demand to peak profitability in fiscal 2023–2024, but has since pulled back sharply as customers digested inventory and deferred orders. Revenue has declined for two straight fiscal years, margins have turned negative, and the most recent full fiscal year (ending May 2026) posted a net loss — a stark reversal from the 50% net margin recorded just two years prior. The silver lining: the balance sheet remains debt-free and exceptionally liquid, and the most recent quarter showed a positive net margin return, hinting that the worst of the cycle may be passing. Long-term, the 5- and 10-year revenue growth picture remains solidly positive, but investors need to weigh cyclical headwinds and customer concentration risks against the company's structural positioning in power semiconductor testing.

Snapshot & Big Picture

Aehr Test Systems (NASDAQ: AEHR) designs and sells wafer-level burn-in and test systems, primarily used to screen silicon carbide and other compound semiconductors before they reach end markets like electric vehicles and industrial power electronics. The company's fiscal year ends in late May. After years of losses, Aehr broke through to consistent profitability in fiscal 2022–2024 as SiC demand surged, but fiscal 2025 and 2026 have been painful retrenchment years as its customer base slowed purchases.

Latest Quarter Snapshot

The most recent quarterly data (period ending May 29, 2026, filed July 2026) is more current than the annual figures and offers a tentatively encouraging signal. Quarterly revenue came in at $18.8M with a gross margin of 42.6% — an improvement over the full-year fiscal 2026 gross margin of 35.3%, suggesting mix or pricing improved late in the year. The operating margin was still slightly negative at -6.4%, but the net margin turned positive at +7.4%, likely reflecting a non-operating or tax item. Capital expenditures for the quarter were minimal at $134K (capex-to-revenue of 0.7%), consistent with the asset-light nature of the business. The current ratio stood at a robust 10.3x, and debt-to-equity was zero — the balance sheet is in strong shape even as the income statement works through a down cycle.

Profitability

Aehr's profitability profile is highly cyclical and tied directly to customer order timing in the SiC space. The company spent most of fiscal 2016–2021 generating losses, broke into consistent profitability in fiscal 2022, hit peak gross margins above 50% in fiscal 2023–2024, and has since given much of that back. The gross margin compression from ~50% to ~35% over just two years reflects revenue declining faster than the company can cut costs, as well as potential pricing and mix pressures. EBITDA, which reached $13.8M in fiscal 2023, flipped to -$11.4M in fiscal 2026. The fiscal 2024 net margin of 50.1% was inflated by a significant non-operating or tax benefit item and should not be taken as a run-rate figure. The underlying operating margin trajectory — from +20.6% in 2023 to -28.3% in 2026 — tells the more honest story of how badly revenue contraction has hit this relatively fixed-cost business.

Financial Health

Despite the profitability downturn, Aehr's balance sheet is a genuine strength. The company carries no debt (debt-to-equity is null or zero across nearly all recent periods, indicating no meaningful long-term debt on the books). The current ratio of 10.3x as of the latest quarter is exceptionally high, reflecting a large cash and short-term asset buffer relative to near-term obligations — the company is not at risk of a liquidity crunch in the near term even while posting operating losses.

Capital expenditure intensity is low and has remained so throughout Aehr's history, which is characteristic of a fabless or asset-light equipment design model. The table below shows capex spending and its ratio to revenue across recent fiscal years:

Capex spiked to $5.0M (8.5% of revenue) in fiscal 2025, which was unusually high relative to historical norms and likely reflected investment during a period of anticipated growth. It has since moderated sharply back to low levels. Overall, Aehr is not a capital-intensive business — reinvestment needs are modest, which means cash burn during loss periods is primarily driven by operating expenses rather than heavy infrastructure spending. The latest quarter's capex of $134K underscores how lean the reinvestment requirements remain.

Growth

The table below shows trailing revenue CAGR across three time windows, computed from annual 10-K filings:

The 3-year CAGR of -8.4% captures the current cyclical downturn in full — revenue has contracted meaningfully from the fiscal 2023–2024 peak as SiC customer demand softened. However, zooming out to 5 years tells a very different story: a +24.7% CAGR from the fiscal 2021 trough reflects the explosive growth phase the company went through as SiC adoption accelerated. The 10-year CAGR of +13.2% provides the most balanced long-run view, showing that despite multi-year loss periods and cyclical swings, Aehr has genuinely grown its revenue base over the decade — the question for investors is whether the current downturn is a temporary digestion period or the beginning of a more structural plateau.

Source Filings

• 10-K filed 2026-07-27 (Fiscal Year End May 29, 2026)
• 10-Q filed 2026-04-08 (Quarter End — most recent quarterly data)